

6. Mehran R, Dangas G, Abizaid AS, et al. Classification and Implications for Long-Term Outcome. *Circulation*. 1999;100:1872-8.
7. Shlofmitz E, Case BC, Chen Y, et al. Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis. *Cardiovasc Revascularization Med* [Internet]. 2021;33:62-7. Available from: <https://www.science-direct.com/science/article/pii/S1553838921002761>
8. Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. *J Am Coll Cardiol*. 2010;56(23):1897-907.
9. Alexandrescu D-M, Mitu O, Costache I, et al. Risk factors associated with intra-stent restenosis after percutaneous coronary intervention. *Exp Ther Med*. 2021;22(4):1-7.
10. TsiGkas GGG, Karantalis V, Hahalis G, et al. Stent restenosis, pathophysiology and treatment options: A 2010 update. *Hell J Cardiol*. 2011;52(2):149-57.
11. Kim MS, Dean LS. In-Stent Restenosis. *Cardiovasc Ther*. 2011;29(3):190-8.
12. Kuramitsu S, Shirai S, Ando K. Mechanism of in-stent restenosis after second-generation drug-eluting stents (DES): Is it different from bare-metal stents and first-generation DES? *J Thorac, Dis*. 2015;7(12):E599--E602.
13. Nusca A, Viscusi MM, Piccirillo F, et al. In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. *Life*. 2022;12(3):1-18.
14. Paramasivam G, Devasia T, Ubaid S, et al. In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario. *Egypt Hear J*. 2019;71(1).
15. Magalhaes MA, Minha S, Chen F, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. *Circ Cardiovasc Interv*. 2014;7(6):768-76.
16. Figini F, Louvard Y, Sheiban I. Use of stent enhancement technique during percutaneous coronary intervention – A case series. *Heart Int*. 2019;13(1):28-31.
17. Figini F, Louvard Y, Sheiban I. Stent Enhancement during Percutaneous Coronary Intervention: Current Role, Technical Tips and Case Examples. *Cardiovasc Revascularization Med*. 2020;21(1):137-43.
18. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79(2):e21-129.
19. Akhtar M, Liu W. Use of intravascular ultrasound vs. optical coherence tomography for mechanism and patterns of in-stent restenosis among bare metal stents and drug eluting stents. *J Thorac, Dis*. 2016;8(1):E104-8.
20. Habara M, Terashima M, Nasu K, et al. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: An optical coherence tomography study. *Eur Heart J Cardiovasc Imaging*. 2013;14(3):276-84.
21. Alfonso F, Pérez-Vizcayno MJ, Dutary J, et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis: Results from a prospective multicenter study (RIBS III [restenosis intra-stent: Balloon angioplasty versus drug-eluting stent]). *JACC Cardiovasc Interv*. 2012;5(7):728-37.
22. Giacoppo D, Alfonso F, Xu B, et al. Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. *J Am Coll Cardiol*. 2020;75(21):2664-78.
23. Siontis GCM, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* (London, England). 2015 Aug;386(9994):655-64.
24. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019;40(2):87-165.
25. Goel SS, Dilip Gajulapalli R, Athappan G, et al. Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis. *Catheter Cardiovasc Interv*. 2016;87(6):1080-91.
26. Wang G, Zhao Q, Chen Q, et al. Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. *Coron Artery, Dis*. 2019;30(7):473-80.
27. Ali RM, Abdul Kader MASK, Wan Ahmad WA, et al. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. *JACC Cardiovasc Interv*. 2019;12(6):558-66.
28. Ahmad WAW, Nuruddin AA, Abdul Kader MASK, et al. Treatment of Coronary De Novo Lesions by a Sirolimus- or Paclitaxel-Coated Balloon. *JACC Cardiovasc Interv*. 2022;15(7):770-9.
29. Basavarajiah S, Mitomo S, Nakamura S, et al. Long-term Outcome following Percutaneous Intervention of Intra-stent Coronary Occlusion and Evaluating the Different Treatment Modalities. *IJC Hear Vasc* [Internet]. 2021;34:100803. Available from: <https://doi.org/10.1016/j.ijcha.2021.100803>
30. Yang J, Mamuti W, Zhang F. Optimal interventional strategy for the treatment of coronary in-stent restenosis. *J Thorac, Dis*. 2015;7(10):1669-71.
31. Aoki Y, De Gregorio J. Optimal Approach for Treating In-Stent Restenosis. *Card Interv Today*. 2018;12(3):49-52.
32. Linares Vicente JA, Ruiz Arroyo JR, Lukic A, et al. 5-Year Results of Cutting or Scoring Balloon Before Drug-Eluting Balloon To Treat in-Stent Restenosis. *REC Interv Cardiol* (English Ed. 2022;4(June 2021):12-8.
33. Kufner S, Joner M, Schneider S, et al. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial. *JACC Cardiovasc Interv*. 2017;10(13):1332-40.
34. Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis. *J Am Coll Cardiol*. 2014;63(24):2659-73.
35. Moscarella E, Ielasi A, Granata F, et al. Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis. *Circ Cardiovasc Interv*. 2016;9(4):1-9.
36. Bossard M, Attinger A, Wolfrum M, et al. Bioresorbable scaffold versus drug coated balloon for treatment of in-stent-restenosis – long-term outcomes of the randomized ABSORB-ISR trial. *Eur Heart J*. 2020;41.
37. Alfonso F, Cuesta J, Pérez-Vizcayno MJ, et al. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study. *JACC Cardiovasc Interv* [Internet]. 2017;10(18):1841-51. Available from: <http://dx.doi.org/10.1016/j.jcin.2017.06.064>
38. Andras A, Hansrani M, Stewart M, et al. Intravascular brachytherapy for peripheral vascular disease. *Cochrane Database Syst Rev*. 2014;2014(1).
39. Condado JA, Waksman R, Calderas C, et al. Two-year follow-up after intracoronary gamma radiation therapy. *Cardiovasc Radiat Med*. 1999;1(1):30-5.
40. Megaly M, Glogozia M, Xenogiannis I, et al. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. *Catheter Cardiovasc Interv*. 2021;97(1):32-8.
41. Megaly M, Glogozia M, Xenogiannis I, et al. Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis. *Cardiovasc Revascularization Med*. 2021;23(xxxx):28-35.
42. Varghese MJ, Bhatheja S, Baber U, et al. Intravascular brachytherapy for the management of repeated multilayered drug-eluting coronary stent restenosis. *Circ Cardiovasc Interv*. 2018;11(10):1-8.
43. Wong B, El-Jack S, Newcombe R, et al. Shockwave Intravascular Lithotripsy for Calcified Coronary Lesions: First Real-World Experience. *J Invasive Cardiol*. 2019 Mar;31(3):46-8.
44. Morabito G, Tripolino C, Tassone EJ, et al. Case of Stent Under-Expansion due to Calcified Plaque Treated with Shockwave Lithoplasty. *Cardiol*. 2018;141(2):75-7.
45. Gulati AS. Interventional Cardiology Coronary stent fracture and in-stent restenosis due to severe calcification treated with shockwave coronary intravascular lithotripsy with drug eluting balloon. 2022;189-93.
46. Alfonso F, Bastante T, Antuña P, et al. Coronary Lithoplasty for the Treatment of Undilatable Calcified De Novo and In-Stent Restenosis Lesions. *JACC Cardiovasc Interv*. 2019;12(5):497-9.
47. Rawlins J, Din JN, Talwar S, et al. Coronary intervention with the excimer laser: Review of the technology and outcome data. *Interv Cardiol Rev Res Resour*. 2016;11(1):27-32.
48. Fukui T. Management of acute aortic dissection and thoracic aortic rupture. *J Intensive Care*. 2018;6(1):1-8.
49. Gupta T, Weinreich M, Greenberg M, et al. Rotational atherectomy: A contemporary appraisal. *Interv Cardiol Rev Res Resour*. 2019;14(3):182-9.
50. Abdel-Wahab M, Toelg R, Byrne RA, et al. High-speed rotational atherectomy versus modified balloons prior to drug-eluting stent implantation in severely calcified coronary lesions: The randomized prepare-CALC trial. Vol. 11, *Circulation: Cardiovascular Interventions*. 2018.
51. Moustapha A, Assali AR, Sdringola S, et al. Percutaneous and surgical interventions for in-stent restenosis: Long-term outcomes and effect of diabetes mellitus. *J Am Coll Cardiol*. 2001;37(7):1877-82.
52. Jintoiu IC, Underwood MJ, Cook SP, et al. Coronary graft failure: State of the art. *Coron Graft Fail State Art*. 2016;1-758.
53. Schömig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: Back to the future? *Circulation*. 2005;112(18):2759-61.
54. Hausleiter J, Kastrati A, Mehili J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial. *Circulation*. 2004;110(7):790-5.